CytomX Therapeutics

About:

CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies.

Website: http://www.cytomx.com

Twitter/X: cytomxinc

Top Investors: Wellington Management, Deerfield, Cormorant Asset Management, Casdin Capital, Perceptive Advisors

Description:

CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

Total Funding Amount:

$345M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2008-01-01

Founders:

Fred Gluck, Nancy E. Stagliano, Patrick Daugherty

Number of Employees:

101-250

Last Funding Date:

2021-01-21

IPO Status:

Public

© 2025 bioDAO.ai